1-1 of 1
Authors: Stephen P. Hack
Journal Article
A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer Free
The Oncologist, Volume 22, Issue 3, March 2017, Pages 264–271, https://doi.org/10.1634/theoncologist.2016-0223
Published: 16 February 2017
